期刊文献+

软骨寡聚基质蛋白在脊柱关节病患者血清中的水平及意义的研究 被引量:3

Research on serum level of cartilage oligomeric matrix protein and its clinical significance in spondyloarthropathies
下载PDF
导出
摘要 目的探讨血清软骨寡聚基质蛋白(COMP)水平与脊柱关节病(SpA)患者病情活动及骨破坏的相关性。方法采用酶联免疫吸附试验(ELISA)方法,检测38例SpA患者、18例正常人及10例注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(商品名益赛普)治疗前后SpA患者血清COMP水平、血沉及C反应蛋白,并行骶髂关节CT分级,记录患者BAS、ASDAS评分及夜间脊柱痛视觉评分(VAS),分析其与COMP的相关性。结果 SpA患者组血清COMP水平为(30.835±8.539)ng/ml,明显高于正常对照组的(12.639±2.939)ng/ml(P<0.01);病情活动组血清COMP水平为(34.168±7.988)ng/ml,明显高于非活动组的(25.122±6.243)ng/ml(P=0.01);治疗后SpA患者血清COMP水平为(17.670±7.199)ng/ml,较治疗前的(35.645±7.381)ng/ml明显下降(P<0.01)。COMP水平与夜间脊柱痛VAS、ESR、CRP及骶髂关节CT分级正相关,与BSADAI、BSAFI、ASDAS-ESR、ASDAS-CRP正相关,与年龄、病程、BASMI及外周关节受累无显著相关。结论 SpA患者血清COMP高水平存在提示病情活动,可能预示明显骨质破坏,血清COMP有可能成为判断SpA疾病活动性和疗效的指标。 Objective To explore the relation of serum level of cartilage oligomeric matrix protein (COMP) with the disease activity and bone destruction. Methods The serum levels of COMP were measured by ELISA in 38 patients with SpA and 18 controls, and those of 10 patients with SpA before and after treatment with Enbrel. The score of BSADAI, BSAFI, BASMI, ASDAS-ESR, ASDAS-CRP and the Night spinal pain (VAS) were recorded and the serum levels of erythrocyte sedimentation rate(ESR), C-reactive protein (CRP) and Sacroiliac joints CT classification were examined at the same time. And their correlation with COMP were analyzed. Results Significantly increased serum level of COMP was found in SpA patients (30.835 +8.539)ng/ml as compared to that in healthy controls (12.639±2.939)ng/ml, there was statistically significant differences (P 〈 0.01) between the two groups. The serum level of COMP was higher in 24 active patients (34.168±7.988)ng/ml than that in 14 inactive patients (25.122±6.243)ng/ml, there was statistically significant differences between these two groups(P = 0.01). The serum level of COMP of ten cases after treatment(17.670±7.199)ng/ml with Enbrel was evidently decreased before treatment (35.645±7.381)ng/ml. The COMP level was positively correlated with ESR ,CRP, BSADAI,BSAFI, ASDAS-ESR,ASDAS-CRP and the Night spinal pain (VAS) and the grade of sacroiliac joint CT changes(P 〈 0.05), and has no significant correlation with age, duration, BASMI and Peripheral joint injury (P 〉 0.05). Conclusion High serum levels of COMP indicat high disease activity and may indicate severe bone destruction. Serum level of COMP can be used for evaluation of disease activity and therapeutic effect of SpA.
出处 《北京医学》 CAS 2011年第10期789-792,共4页 Beijing Medical Journal
关键词 软骨寡聚基质蛋白 血清阴性脊柱关节病 酶联免疫吸附试验 Cartilage oligomeric matrix protein (comp) Spondyloarthropathies ( SpA ) ELISA
  • 相关文献

参考文献9

  • 1Lukas C, Landewe R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis,2009,68:18-24.
  • 2黄烽.脊柱关节病总论//蒋明,DAVID YU.林孝义.中华风湿病学[M].北京:华夏出版社,2004:1004-1005.
  • 3潘解萍,吴敏,马英淳,孙茹蓉.类风湿关节炎患者血清软骨寡聚基质蛋白水平及意义的研究[J].中华风湿病学杂志,2008,12(9):610-612. 被引量:9
  • 4Sharif M, Kirwan JR, Elson C J, et al. Suggestion of nonlinear or- phasic progression of knee osteoarthritis based on measurents of serum cartilage oligomeric matrix protein levels over five years. Arthritis Rheum,2004,50:2479-2488.
  • 5SAXNE, T. & D. HEINEGARD. Cartilage oligomeric matrix pro- tein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol,1992,31:583-591.
  • 6Riessm R, Fenchel M, Chen H, et al. Arterioscler Thromb Vasc, Biol,2001,21:47-54.
  • 7许漫龙,林智明,廖泽涛,黄进贤,李丽,魏艳林,魏秋静,李秋霞,谢颖颖,张艳丽,李天旺,古洁若.强直性脊柱炎新的疾病活动性指数在中国患者中的应用价值研究[J].中华风湿病学杂志,2010,14(3):177-181. 被引量:11
  • 8van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly dis~ criminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis,2009,68:1811-1818.
  • 9Hunter D J, Li J, Lavalley M, et al. Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis:the Boston osteoarthritis knee study. Arthritis Res Ther.2007,9:108.

二级参考文献22

  • 1Skoumal M, Kolarz G, Klingler A. Serum levels of cartilage oligomeric matrix protein: a predicting factor and a valuable parameter for disease management in rheumatoid arthritis. Scand J Rheumatol, 2003, 32: 156-161.
  • 2董怡.类风湿关节炎//叶任高.内科学.6版.北京:人民卫生出版社,2006:885-891.
  • 3Marti C, Neidhart M, Gerber T, et al. Cartilage oligomeric matrix protein: the role of a non-collagen cartilage matrix proteinas a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis. Zeitschrift fur Rheumatologie, 1999, 58: 79-87.
  • 4Crukic M, Mansson B, Larsson L. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther, 2003, 5: 181-185.
  • 5Larsson E, Erlandsson-Harris H, Larsson A, et al. Cortieosternid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP. Rheumatol, 2004, 43: 428-434.
  • 6Momohara S, Yamanaka-H, Holledge MM, et al. Cartilage oligomeric matrix protein in serum and syuovial fluid of rheumatoid arthritis: potential use as a marker for joint cartilage damage. Mod Rheumatol, 2004, 14: 356-360.
  • 7Gomez-Barrena E, Lindroos L, Ceponis A, et al. Cartilage oligomerie matrix protein (COMP) is modified by intra-articular liposomal clodronate in an experimental model of arthritis. Clin Exp Rheumatol, 2006, 24: 622-628.
  • 8Wislowska M, Jablonska B. Serum cartilage ohgomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis. Clin Rheumatol, 2005, 24: 278-284.
  • 9Skoumal M, Haberhauer G, Fevertag J, et al. Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment. Rheumatol Int, 2006, 26: 1001-1004.
  • 10Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis, 2005, 64: 196-201.

共引文献18

同被引文献49

  • 1李子荣.股骨头骨坏死的ARCO分期[J].中华外科杂志,1996,34(3):186-187. 被引量:185
  • 2夏睿,董启榕,戴俭英,赵婷,孙辉.兔创伤性骨性关节炎软骨细胞中基质金属蛋白酶13表达增加[J].基础医学与临床,2007,27(2):202-203. 被引量:9
  • 3Fife RS, Brandt KD. Cartilage matrix glycoprotein is present in serum in experimental canine osteoarthritis [J]. J Clin Invest, 1989,84(5): 1432-1439.
  • 4Aleom JL, Merritt TM, Farach-Carson MC, et al. Ribozyme-mediated reduction of wild-type and mutant cartilage oligomerie matrix protein (COMP)mRNA and protein[J]. RNA, 2009,15(4):686-695.
  • 5Rock MJ, Holden P, Horton WA, et al. Cartilage oligomeric matrix protein promotes cell attachment via two independent mechanisms in- volving CD47 and alphaVbeta3 integrin [J]. Mol Cell Bioehem, 2010,338(1-2) :215-224.
  • 6Bender AL, Da Silveira IG, Von Muhlen CA, et al. High specificity but low sensitivity of the cartilage oligomeric matrix protein(COMP) test in rheumatoid arthritis and osteoarthritis [J]. Clin Chom Lab Med, 2010,48(45): 69-570.
  • 7Tseng S, Reddi AH, Di Cesare PE. Cartilage Oligomeric Matrix Pro- tein(COMP):A Biomarker of Arthritis[J]. Biomark Insights, 2009,17 (4):33-44.
  • 8Toehigi Y, Buckwalter JA, Martin JA, et al. Distribution and progres- sion of chondrocyte damage in a whole-organ model of human ankle intra-articular fracture[J]. J Bone JointSurg Am, 2011,93(6):533-539.
  • 9Helmark IC, Petersen MC, Christensen HE, et al. Moderate loading of the human osteoarthritic knee joint leads to lowering of intraarticular cartilage oligomeric matrix protein [J]. Rheumatology, 2012,32(4): 1009-1014.
  • 10Gagarina V, Carlberg AL, Pereira-Mouries L, et al. Cartilage oligomeric matrix protein protects cells against death by elevating members of the IAP family of survival proteins [J]. J Biol Chem, 2008,283(1):648-659.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部